期刊文献+

骨肉瘤靶向治疗的研究进展 被引量:4

下载PDF
导出
摘要 骨肉瘤是一种多因素和多基因协同作用、经过多个阶段最终形成的极其复杂的多基因遗传性疾病。随着细胞生物学及分子生物学的发展,现代医学对骨肉瘤的认识逐渐上升到分子水平。从分子水平探讨骨肉瘤的发生和发展已成为现代生物医学研究的热点问题。目前,国外已有大量的相关文献提出了骨肉瘤多个可能的信号通路,靶向受体,信号传导抑制剂等。本文主要从骨肉瘤的分子机制,免疫系统分子靶向治疗,骨代谢涉及的细胞外及细胞间的信号通路,以及新的治疗靶点和药物运输系统等方面进行综述研究。
出处 《西南军医》 2017年第5期438-443,共6页 Journal of Military Surgeon in Southwest China
基金 2017年中央引导地方科技发展专项(2017CT5028) 娄底市科技计划项目(娄财企指[2016]384号)
  • 相关文献

参考文献1

二级参考文献55

  • 1Ma XM, Blenis J. Molecular mechanisms of mTOR-mediated translational control. Nat Rev Mol Cell Biol 2009; 10: 30-18.
  • 2Peterson TR, Laplante M, Thoreen CC, Sancak Y, Kang SA, Kuehl WM, et a/. DEPTOR is an mTOR inhibitor frequently overexpressed in multiple myeloma cells and required for their survival. Cell 2009; 137: 873-86.
  • 3Hara K, Maruki Y, Long XM, Yoshino K, Oshiro N, Hidayat S, et a/. Raptor, a binding partner of target of rapamycin (TOR), mediates TOR action. Cell 2002; 110:177-89.
  • 4Sarbassov DD, Ali SM, Kim DH, Guertin DA, Latek RR, Erdjument-Bromage H, et al. Rictor, a novel binding partner of mTOR, defines a rapamycin-insensitive and raptor-independent pathway that regulates the cytoskeleton. Curr Biol 2004; 14; 1296-302.
  • 5Hudes G, Carducci M, Tomczak P, Dutcher J, Figlin R, Kapoor A, et a/. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 2007; 356: 2271-81.
  • 6Motzer RJ, Escudier B, Oudard S, Hutson TE, Porta C, Bracarda S, et al. Efficacy of everolimus in advanced renal cell carcinoma: a doubleblind, randomised, placebo-controlled phase III trial. Lancet 2008; 372: 449-56.
  • 7Garcia-Echeverria C. Allosteric and ATP-competitive kinase inhibitors of mTOR for cancer treatment. Bioorg Med Chem Lett 2010; 20: 4308-12.
  • 8Zhang Y, Zheng XF. mTOR-independent 4E-BP1 phosphorylation is associated with cancer resistance to mTOR kinase inhibitors. Cell cycle 2012; 11: 594-603.
  • 9Don AS, Zheng XF. Recent clinical trials of mTOR-targeted cancer therapies. Rev Recent Clin Trials 2011; 6: 24-35.
  • 10Llovet JM, Hernandez-Gea V. Hepatocellular carcinoma: reasons for phase III failure and novel perspectives on trial design. Clin Cancer Res 2014; 20: 2072-9.

共引文献10

同被引文献39

引证文献4

二级引证文献5

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部